TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33337294

Group type: EXPERIMENTAL
Intervention: Home automation (HA) training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional training (Control Group)
Number of subjects: 40
Study: 34499045

Group type: EXPERIMENTAL
Intervention: SmokeFree buddy app
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (self-monitoring)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study: 34530484

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 71
Study: 33096985

Group type: EXPERIMENTAL
Intervention: Confirmed CHD diagnosis
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Correct MI diagnosis in patients with confirmed CHD
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Non-complex CHD diagnosis
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Complex CHD diagnosis
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Incorrect MI diagnoses
Number of subjects: 249
Study: 36360973

Group type: EXPERIMENTAL
Intervention: SGC and SP combined intervention group
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: SP intervention group
Number of subjects: 237

Group type: COMPARATOR
Intervention: Regular practice group
Number of subjects: 237
Study: 32757504

Group type: EXPERIMENTAL
Intervention: Individually uptitrated, high-dose baclofen (30-300 mg/d)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 33742551

Group type: EXPERIMENTAL
Intervention: 0.12 mg ranibizumab
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.20 mg ranibizumab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessment
Number of subjects: 20
Study: 33722257

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (ORS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Spring water
Number of subjects: 10
Study: 33019775

Group type: EXPERIMENTAL
Intervention: SPOTONE ML predictor
Number of subjects: 0
Study: 33509350

Group type: EXPERIMENTAL
Intervention: Cardiovascular screening before transplant listing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current protocols for cardiovascular workup
Number of subjects: 0
Study: 32004317

Group type: EXPERIMENTAL
Intervention: Clinical decision rule (Feverkidstool) guiding antibiotic prescription, withholding antibiotics in children with a low or intermediate predicted risk of bacterial pneumonia (≤10%).
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Clinical decision rule (Feverkidstool) guiding antibiotic prescription.
Number of subjects: 999
Study: 36030249

Group type: EXPERIMENTAL
Intervention: 10 mg memantine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Memantine vs. Placebo
Number of subjects: 20
Study: 33499551

Group type: COMPARATOR
Intervention: Novel detoxification method
Number of subjects: 32
Study: 35367170

Group type: EXPERIMENTAL
Intervention: Low-dose rivaroxaban (2.5 mg twice daily for 30 days) + Dual Antiplatelet Therapy (DAPT)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Only Dual Antiplatelet Therapy (DAPT)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Low-dose rivaroxaban (2.5 mg twice daily for 30 days) + DAPT
Number of subjects: 279

Group type: COMPARATOR
Intervention: Only DAPT
Number of subjects: 279
Study: 33135319

Group type: EXPERIMENTAL
Intervention: Music intervention (30-min session of music of their own choice)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard analgesia (control group)
Number of subjects: 70
Study: 33361487

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 30 min, 3 sessions per week for 4 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 26
Study: 618142129

Group type: EXPERIMENTAL
Intervention: 800 mg synthetic GABA
Number of subjects: 30

Group type: COMPARATOR
Intervention: 800 mg microcrystalline cellulose (placebo)
Number of subjects: 30
Study: 36047565

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 263

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 263
Study: 34006464

Group type: EXPERIMENTAL
Intervention: Continuous subcuticular suture urethroplasty (Group A)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Interrupted subcuticular suture urethroplasty (Group B)
Number of subjects: 260
Study: 32821939

Group type: EXPERIMENTAL
Intervention: 5-day remdesivir (n=199)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: 10-day remdesivir (n=197)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Standard care (n=200)
Number of subjects: 596
Study: 35031521

Group type: EXPERIMENTAL
Intervention: Routine care plus a twice‐daily application‐based mindful meditation program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine care plus educational pamphlets (control arm)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (meditation and control)
Number of subjects: 56
Study: 36383914

Group type: EXPERIMENTAL
Intervention: Adjuvant lomustine
Number of subjects: 4
Study: 34624839

Group type: EXPERIMENTAL
Intervention: activL device
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: No preoperative narcotics use
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Preoperative factors (unrestricted full-time work, working manual labor after index back injury)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Older age, greater VAS-leg pain score, greater ODI score, female sex, working manual labor before back injury
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Preoperative BMI, VAS-back pain score, back pain duration ≥ 1 year, SF-36 physical component summary score, recreational activity
Number of subjects: 283
Study: 32532326

Group type: EXPERIMENTAL
Intervention: Extended doxycycline treatment (100 mg twice daily for 1 week before and after oocyte retrieval)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Salpingectomy (laparoscopic salpingectomy with coagulation of mesosalpinx)
Number of subjects: 305
Study: 35042948

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (d-amp) 10 or 20 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (d-amp)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 34758698

Group type: EXPERIMENTAL
Intervention: Watching educational videos on the harms of waterpipe tobacco smoking (WTS)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Video focused on physical harms of WTS
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: All four videos (physical harms, myths about WTS, addiction, harms to others)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Not watching a video
Number of subjects: 208
Study: 32603351

Group type: EXPERIMENTAL
Intervention: BFR (blood flow restriction) training (4 sets at 30% 1-RM until failure)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NoBFR training (4 sets at 30% 1-RM until failure)
Number of subjects: 21

Group type: COMPARATOR
Intervention: BFR training
Number of subjects: 21

Group type: COMPARATOR
Intervention: NoBFR training
Number of subjects: 21
Study: 35250287

Group type: EXPERIMENTAL
Intervention: Sunscreen A (broad spectrum sunscreen with anti-inflammatory agent)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sunscreen A
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sunscreen B (regular sunscreen)
Number of subjects: 59
Study: 35761117

Group type: EXPERIMENTAL
Intervention: PSMA PET/CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT+WBBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT
Number of subjects: 0
Study: 33834625

Group type: COMPARATOR
Intervention: Citrus aurantium standardised reference materials (SRMs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pre‐workout supplements
Number of subjects: 12
Study: 32484736

Group type: EXPERIMENTAL
Intervention: Duration of eating disorder behaviours (EDBs)
Number of subjects: 6034

Group type: EXPERIMENTAL
Intervention: Age of onset of eating disorder behaviours (EDBs)
Number of subjects: 6034
Study: 36001790

Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 34058100

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC group)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Conventional Exercise (EX group)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 543
Study: 35700837

Group type: COMPARATOR
Intervention: Liraglutide (0.6 mg/day escalating to 3.0 mg/day over 5 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lorcaserin (10 mg twice daily for 12 weeks)
Number of subjects: 54
Study: 35608694

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with 450-nm blue LED and curcumin photosensitizer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with low-level laser therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group treated with nystatin
Number of subjects: 30
Study: 36261261

Group type: EXPERIMENTAL
Intervention: Bupivacaine alone (Bupi group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Liposomal bupivacaine plus bupivacaine (LB group)
Number of subjects: 76
Study: 33663582

Group type: EXPERIMENTAL
Intervention: Dangguixu-san (DS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 32683741

Group type: EXPERIMENTAL
Intervention: Cross-cylinder method
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single method
Number of subjects: 50
Study: 36455242

Group type: EXPERIMENTAL
Intervention: Pitch Elevation Training (PET)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Articulation-Resonance Training (ART)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of PET and ART
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham Training
Number of subjects: 30
Study: 33560322

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (transfusion triggered by hemoglobin ≤8; n=342)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (transfusion triggered by hemoglobin ≤10 g/dL; n=324)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 668

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 668
Study: 32728162

Group type: EXPERIMENTAL
Intervention: Hypospadias cases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34417649

Group type: EXPERIMENTAL
Intervention: #Tamojunto (intervention group)
Number of subjects: 6390

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 6390

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 6390
Study: 34688059

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (5 sessions of 60 minutes per week for 8 weeks)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (health education program)
Number of subjects: 330
Study: 33234786

Group type: EXPERIMENTAL
Intervention: Attention‐based U‐Net
Number of subjects: 75

Group type: COMPARATOR
Intervention: Generic 3‐D U‐Net
Number of subjects: 75
Study: 34430896

Group type: EXPERIMENTAL
Intervention: Expandable femoral fixation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Suspensory femoral fixation
Number of subjects: 48
Study: 35833528

Group type: EXPERIMENTAL
Intervention: Guided Periodontal Infection Control (GPIC)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Conventional Non-Surgical Therapy (CNST)
Number of subjects: 615
Study: 33843245

Group type: EXPERIMENTAL
Intervention: Trilogy lithotripter
Number of subjects: 100

Group type: COMPARATOR
Intervention: ShockPulse‐SE lithotripter
Number of subjects: 100
Study: 33272623

Group type: EXPERIMENTAL
Intervention: 6 μg/d of follitropin delta
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 9 μg/d of follitropin delta
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 12 μg/d of follitropin delta
Number of subjects: 158

Group type: COMPARATOR
Intervention: 150 IU/d of follitropin beta (control)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: follitropin delta
Number of subjects: 158
Study: 35172199

Group type: EXPERIMENTAL
Intervention: Gamified curriculum using Kahoot!
Number of subjects: 73

Group type: COMPARATOR
Intervention: Nongamified curriculum (control group)
Number of subjects: 73
Study: 34330170

Group type: EXPERIMENTAL
Intervention: suvorexant 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: lormetazepam 2 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 32611863

Group type: EXPERIMENTAL
Intervention: Ozonated water
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Green tea extract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 34470053

Group type: EXPERIMENTAL
Intervention: Anodal high definition-transcranial direct current stimulation (HD-tDCS) over dlPFC
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Anodal high definition-transcranial direct current stimulation (HD-tDCS) over PPC
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 68
Study: 34622762

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg or 300 mg every four weeks
Number of subjects: 173
Study: 32726475

Group type: EXPERIMENTAL
Intervention: ENACT group visits (n=55), two 2-hour sessions discussing ACP topics and using ACP tools.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control arm (n=55), received Conversation Starter Kit and Medical Durable Power of Attorney form by mail.
Number of subjects: 110
Study: 34607738

Group type: EXPERIMENTAL
Intervention: Hand therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Independent exercise (IE)
Number of subjects: 57
Study: 32959898

Group type: EXPERIMENTAL
Intervention: Behavioural management program
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard communication approach
Number of subjects: 71
Study: 32360042

Group type: EXPERIMENTAL
Intervention: Polished surface (400‐1200‐grit SiC papers)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Roughened surface (200‐grit SiC papers)
Number of subjects: 60
Study: 33966428

Group type: EXPERIMENTAL
Intervention: Tiaochang Xiaoliu Decoction Granules (TXDG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TXDG mimetic agent
Number of subjects: 0
Study: 36458325

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg and colloidal bismuth 200 mg each given twice a day for 10 days (V10)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg and colloidal bismuth 200 mg each given twice a day for 14 days (V14)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg with amoxicillin 1000 mg, furazolidone 100 mg and colloidal bismuth 200 mg each given twice a day for 14 days (E14)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg daily (V10)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg daily (V14)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg (E14)
Number of subjects: 234
Study: 34275866

Group type: EXPERIMENTAL
Intervention: Door-to-door HIV self-testing (HIVST)
Number of subjects: 2582

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 2582
Study: 32960847

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitors (nivolumab, pembrolizumab, cemiplimab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PD-1 inhibitors
Number of subjects: 0
Study: 33782985

Group type: EXPERIMENTAL
Intervention: BiOSS Expert (biodegradable polymer eluting paclitaxel)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: BiOSS LIM (biodegradable polymer eluting sirolimus)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Regular drug-eluting stent (rDES)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: BiOSS Expert
Number of subjects: 445

Group type: COMPARATOR
Intervention: rDES
Number of subjects: 445
Study: 36335048

Group type: EXPERIMENTAL
Intervention: aboBoNT‐A 500U
Number of subjects: 186

Group type: COMPARATOR
Intervention: aboBoNT‐A 300U
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 33378989

Group type: EXPERIMENTAL
Intervention: Combination of favipiravir and tocilizumab
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 26
Study: 32200506

Group type: EXPERIMENTAL
Intervention: Optimal Pulse Technology (OPT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intense Regulated Pulsed Light (IRPL)
Number of subjects: 62
Study: 34301226

Group type: EXPERIMENTAL
Intervention: LEAP (CompuLsive Exercise Activity TheraPy)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 128
Study: 36184345

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Consult as usual (CAU)
Number of subjects: 265
Study: 34474282

Group type: EXPERIMENTAL
Intervention: Post-randomization NMB
Number of subjects: 548

Group type: COMPARATOR
Intervention: Not receiving post-randomization NMB
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: NMB use
Number of subjects: 548
Study: 35894226

Group type: EXPERIMENTAL
Intervention: Backward span training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Forward span training
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 60
Study: 32619206

Group type: EXPERIMENTAL
Intervention: Theta binaural beat (TBB) auditory stimulus
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (pink sound and carrier tones without TBB)
Number of subjects: 64
Study: 32692000

Group type: EXPERIMENTAL
Intervention: COVID-19 treatment in emergency departments
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Clinical variables
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Complementary test findings
Number of subjects: 1000
Study: 36451216

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) for Plasmodium falciparum
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/PPQ) for Plasmodium falciparum
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) for Plasmodium vivax
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/PPQ) for Plasmodium vivax
Number of subjects: 379
Study: 33952552

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 1132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1132
Study: 32847494

Group type: EXPERIMENTAL
Intervention: Online education intervention (six-week group-based)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 150
Study: 33290336

Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate (BMAC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no enhancement)
Number of subjects: 12
Study: 33910468

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traditional Care (TC)
Number of subjects: 65
Study: 32979576

Group type: EXPERIMENTAL
Intervention: High-content screening (HCS) strategy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Classic isolation procedure
Number of subjects: 104
Study: 33023276

Group type: EXPERIMENTAL
Intervention: Nuun electrolyte tablets (single dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nuun electrolyte tablets (double dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 18
Study: 35562742

Group type: EXPERIMENTAL
Intervention: Legume-based DASH diet
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional DASH diet
Number of subjects: 300
Study: 33469752

Group type: EXPERIMENTAL
Intervention: Training alone
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Training and municipal support (less intensive)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Training and municipal support (more intensive)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 58
Study: 35211253

Group type: EXPERIMENTAL
Intervention: Temozolomide combined with radiotherapy (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Radiotherapy alone (Group B)
Number of subjects: 120
Study: 34053798

Group type: EXPERIMENTAL
Intervention: Lateral crural overlay (LCO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lateral crural transposition
Number of subjects: 40
Study: 32788150

Group type: EXPERIMENTAL
Intervention: Active symptom monitoring smartphone app
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual management
Number of subjects: 81
Study: 36004715

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis HN019 (n=64)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus rhamnosus HN001 (n=64)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (n=64)
Number of subjects: 192
Study: 34418549

Group type: EXPERIMENTAL
Intervention: 5% ALA-PDT treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Red-light treatment
Number of subjects: 7
Study: 33775200

Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study: 32303515

Group type: EXPERIMENTAL
Intervention: SAFE plus treatment‐as‐usual (TAU)
Number of subjects: 51

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 51
Study: 35152272

Group type: EXPERIMENTAL
Intervention: Supervised multimodal (aerobic and resistance) exercise (EX)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-intervention serum from EX
Number of subjects: 25

Group type: COMPARATOR
Intervention: Self-directed exercise control group (CON)
Number of subjects: 25
Study: 34221078

Group type: EXPERIMENTAL
Intervention: Backward Walking (BW) combined with conventional treatments
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional treatments alone (Control Group)
Number of subjects: 32
Study: 36223293

Group type: COMPARATOR
Intervention: Disposable ports
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Reprocessed disposable ports
Number of subjects: 473